Sinocelltech(SH:688520) Jin Rong Jie·2025-05-14 10:46Group 1 - The core viewpoint of the articles highlights the performance and valuation of Shenzhou Cell, which closed at 36.28 yuan with a PE ratio of 159.15 times, significantly higher than the industry average of 57.93 times [1][2] - Shenzhou Cell's total market capitalization is 16.157 billion yuan, ranking 71st in the industry based on PE ratio [1][2] - As of the first quarter of 2025, 13 institutions hold shares in Shenzhou Cell, with a total holding of 331.2791 million shares valued at 13.496 billion yuan [1] Group 2 - Shenzhou Cell focuses on the research and development of innovative biopharmaceuticals with competitive advantages, targeting areas such as malignant tumors, autoimmune diseases, infectious diseases, and genetic disorders [1] - The company's main products include recombinant protein drugs and antibody drugs, supported by a comprehensive platform for innovative drug discovery [1] - In the latest financial report for Q1 2025, Shenzhou Cell reported revenue of 520 million yuan, a year-on-year decrease of 15.15%, and a net profit of 63.7678 million yuan, down 14.06%, with a gross margin of 94.88% [1]